S-217622, a SARS-CoV-2 main protease inhibitor, decreases viral load and ameliorates COVID-19 severity in hamsters
M Sasaki, K Tabata, M Kishimoto, Y Itakura… - Science translational …, 2022 - science.org
In parallel with vaccination, oral antiviral agents are highly anticipated to act as
countermeasures for the treatment of the coronavirus disease 2019 (COVID-19) pandemic …
countermeasures for the treatment of the coronavirus disease 2019 (COVID-19) pandemic …
[HTML][HTML] Small molecules in the treatment of COVID-19
S Lei, X Chen, J Wu, X Duan, K Men - Signal Transduction and Targeted …, 2022 - nature.com
The outbreak of COVID-19 has become a global crisis, and brought severe disruptions to
societies and economies. Until now, effective therapeutics against COVID-19 are in high …
societies and economies. Until now, effective therapeutics against COVID-19 are in high …
A randomized phase 2/3 study of ensitrelvir, a novel oral SARS-CoV-2 3C-like protease inhibitor, in Japanese patients with mild-to-moderate COVID-19 or …
H Mukae, H Yotsuyanagi, N Ohmagari… - Antimicrobial agents …, 2022 - Am Soc Microbiol
This multicenter, double-blind, phase 2a part of a phase 2/3 study assessed the efficacy and
safety of ensitrelvir, a novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) …
safety of ensitrelvir, a novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) …
[HTML][HTML] Inhaled fluticasone furoate for outpatient treatment of Covid-19
DR Boulware, CJ Lindsell, TG Stewart… - … England Journal of …, 2023 - Mass Medical Soc
Background The effectiveness of inhaled glucocorticoids in shortening the time to symptom
resolution or preventing hospitalization or death among outpatients with mild-to-moderate …
resolution or preventing hospitalization or death among outpatients with mild-to-moderate …
Effect of ivermectin vs placebo on time to sustained recovery in outpatients with mild to moderate COVID-19: a randomized clinical trial
Importance The effectiveness of ivermectin to shorten symptom duration or prevent
hospitalization among outpatients in the US with mild to moderate symptomatic COVID-19 is …
hospitalization among outpatients in the US with mild to moderate symptomatic COVID-19 is …
Sensitivity to vaccines, therapeutic antibodies, and viral entry inhibitors and advances to counter the SARS-CoV-2 Omicron variant
H Zhou, M Møhlenberg, JC Thakor… - Clinical microbiology …, 2022 - Am Soc Microbiol
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) keeps evolving and
mutating into newer variants over time, which gain higher transmissibility, disease severity …
mutating into newer variants over time, which gain higher transmissibility, disease severity …
[PDF][PDF] An update on COVID-19: SARS-CoV-2 variants, antiviral drugs, and vaccines
VE Hillary, SA Ceasar - Heliyon, 2023 - cell.com
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a highly contagious and
pathogenic virus that first appeared in late December 2019. This SARS-CoV-2 causes an …
pathogenic virus that first appeared in late December 2019. This SARS-CoV-2 causes an …
[HTML][HTML] Fast-track development of vaccines for SARS-CoV-2: the shots that saved the world
In December 2019, an outbreak emerged of severe acute respiratory syndrome coronavirus
2 (SARS-CoV-2) which leads to coronavirus disease 2019 (COVID-19). The World Health …
2 (SARS-CoV-2) which leads to coronavirus disease 2019 (COVID-19). The World Health …
Coronavirus disease 2019 convalescent plasma outpatient therapy to prevent outpatient hospitalization: a meta-analysis of individual participant data from 5 …
Background Outpatient monoclonal antibodies are no longer effective and antiviral
treatments for coronavirus disease 2019 (COVID-19) disease remain largely unavailable in …
treatments for coronavirus disease 2019 (COVID-19) disease remain largely unavailable in …
Effectiveness of COVID-19 treatment with nirmatrelvir–ritonavir or molnupiravir among US veterans: target trial emulation studies with one-month and six-month …
KL Bajema, K Berry, E Streja, N Rajeevan… - Annals of internal …, 2023 - acpjournals.org
Background: Information about the effectiveness of oral antivirals in preventing short-and
long-term COVID-19–related outcomes in the setting of Omicron variant transmission and …
long-term COVID-19–related outcomes in the setting of Omicron variant transmission and …